Emergent: Emergent BioSolutions and Rocketvax form joint venture for development of intranasal vaccine candidates

Emergent BioSolutions and Swiss biotech Rocketvax have announced that Emergent will make a strategic investment in Rocketvax parent company Swiss Rockets and will take over manufacturing and commercialization activities for 4 of Rocketvax's intranasal vaccine candidates. Rocketvax's pipeline includes live attenuated intranasal vaccines for melanoma and multiple sclerosis in addition to vaccines against viral diseases, including [...]